Literature DB >> 32716364

Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants.

James W Young.   

Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) benefits increasing numbers of patients with otherwise lethal diseases. Graft-versus-host disease (GVHD), however, remains one of the most potentially life-threatening complications due to its own comorbidities and the side effects of its treatment. In this issue of the JCI, two groups have turned dogma on its head by providing evidence for alternative mechanisms of acute GVHD (aGVHD) in humans. The principle of donor T cell reactivity elicited by host antigen-presenting cells (APCs) expressing MHC-encoded major HLA disparities or expressing minor histocompatibility antigen (miHA) differences presented by identical HLA molecules remains intact. These reports, however, demonstrate that GVHD can additionally result from peripheral host T cells resident in skin and gut being stimulated against donor APCs in the form of monocyte-derived macrophages. Moreover, these donor monocyte-derived macrophages can themselves mediate cytopathic effects against resident host T cells in skin explants and against a keratinocyte-derived cell line.

Entities:  

Year:  2020        PMID: 32716364      PMCID: PMC7456243          DOI: 10.1172/JCI140064

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

Review 1.  Molecules and mechanisms of the graft-versus-leukaemia effect.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Nat Rev Cancer       Date:  2004-05       Impact factor: 60.716

2.  Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.

Authors:  Pere Barba; Patrick Hilden; Sean M Devlin; Molly Maloy; Djamilia Dierov; Jimmy Nieves; Matthew D Garrett; Julie Sogani; Christina Cho; Juliet N Barker; Nancy A Kernan; Hugo Castro-Malaspina; Ann A Jakubowski; Guenther Koehne; Esperanza B Papadopoulos; Susan Prockop; Craig Sauter; Roni Tamari; Marcel R M van den Brink; Scott T Avecilla; Richard Meagher; Richard J O'Reilly; Jenna D Goldberg; James W Young; Sergio Giralt; Miguel-Angel Perales; Doris M Ponce
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-23       Impact factor: 5.742

3.  Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease.

Authors:  Motoko Koyama; Rachel D Kuns; Stuart D Olver; Neil C Raffelt; Yana A Wilson; Alistair L J Don; Katie E Lineburg; Melody Cheong; Renee J Robb; Kate A Markey; Antiopi Varelias; Bernard Malissen; Günter J Hämmerling; Andrew D Clouston; Christian R Engwerda; Purnima Bhat; Kelli P A MacDonald; Geoffrey R Hill
Journal:  Nat Med       Date:  2011-11-29       Impact factor: 53.440

4.  Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation.

Authors:  Marco Mielcarek; Anna Yasmine Kirkorian; Robert C Hackman; Jeremy Price; Barry E Storer; Brent L Wood; Marylene Leboeuf; Milena Bogunovic; Rainer Storb; Yoshihiro Inamoto; Mary E Flowers; Paul J Martin; Matthew Collin; Miriam Merad
Journal:  Transplantation       Date:  2014-09-15       Impact factor: 4.939

5.  Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation.

Authors:  Effie W Petersdorf; Mats Bengtsson; Dianne De Santis; Valerie Dubois; Katharina Fleischhauer; Ted Gooley; Mary Horowitz; J Alejandro Madrigal; Mari Malkki; Caroline McKallor; Yasuo Morishima; Machteld Oudshoorn; Stephen R Spellman; Jean Villard; Phil Stevenson; Mary Carrington
Journal:  J Clin Oncol       Date:  2020-06-01       Impact factor: 44.544

6.  Langerhans cells are not required for graft-versus-host disease.

Authors:  Hongmei Li; Daniel H Kaplan; Catherine Matte-Martone; Hung Sheng Tan; Srividhya Venkatesan; Kody Johnson; Anthony J Demetris; Jennifer McNiff; Mark J Shlomchik; Warren D Shlomchik
Journal:  Blood       Date:  2010-10-13       Impact factor: 22.113

7.  Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease.

Authors:  Miriam Merad; Petra Hoffmann; Erik Ranheim; Sarah Slaymaker; Markus G Manz; Sergio A Lira; Israel Charo; Donald N Cook; Irving L Weissman; Samuel Strober; Edgar G Engleman
Journal:  Nat Med       Date:  2004-04-18       Impact factor: 53.440

8.  Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide.

Authors:  Christopher G Kanakry; Sudipto Ganguly; Marianna Zahurak; Javier Bolaños-Meade; Christopher Thoburn; Brandy Perkins; Ephraim J Fuchs; Richard J Jones; Allan D Hess; Leo Luznik
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956

9.  Donor monocyte-derived macrophages promote human acute graft-versus-host disease.

Authors:  Laura Jardine; Urszula Cytlak; Merry Gunawan; Gary Reynolds; Kile Green; Xiao-Nong Wang; Sarah Pagan; Maharani Paramitha; Christopher A Lamb; Anna K Long; Erin Hurst; Smeera Nair; Graham H Jackson; Amy Publicover; Venetia Bigley; Muzlifah Haniffa; A J Simpson; Matthew Collin
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

10.  Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow.

Authors:  R Korngold; J Sprent
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

View more
  1 in total

1.  Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation.

Authors:  Jun Zou; Piyanuch Kongtim; Betül Oran; Vasilis Kosmoliaptsis; Yudith Carmazzi; Junsheng Ma; Liang Li; Gabriela Rondon; Samer Srour; Hannah C Copley; David Partlow; Stefan O Ciurea; Uri Greenbaum; Qing Ma; Elizabeth J Shpall; Richard E Champlin; Kai Cao
Journal:  Haematologica       Date:  2022-04-01       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.